Therapies that inhibit lipid metabolic pathways include those targeting acetyl‐CoA carboxylase in non‐small cell lung cancer and hepatocellular carcinoma as well as those targeting FASN in lung [46, 47], ovarian, and prostate cancers [48]. The gene discussed is FASN; the disease is prostate cancer.